TY - JOUR
T1 - Sarcomeric genotyping in hypertrophic cardiomyopathy
AU - Van Driest, Sara L.
AU - Ommen, Steve R.
AU - Tajik, A. Jamil
AU - Gersh, Bernard J.
AU - Ackerman, Michael J.
N1 - Funding Information:
This study was supported by a Mayo Foundation clinical research award to Dr Ackerman. Dr Ackerman is an established investigator of the American Heart Association.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2005/4
Y1 - 2005/4
N2 - OBJECTIVE: To pool results from studies of patients with hypertrophic cardiomyopathy (HCM) to elucidate important phenotypic differences among genotypes. MATERIAL AND METHODS: Data published from November 1998 through November 2004 were gathered and compared from unrelated study population genotyping studies from the Mayo Clinic (Rochester, Minn), Harvard Medical School (Boston, Mass), France, Germany, Sweden, Finland, and Spain. Standard statistical analysis techniques were used to pool and compare date across genotypes with respect to frequency of mutations, age at diagnosis, and degree of hypertrophy (left ventricular wall thickness). RESULTS: The French study populated harbored the highest frequency of mutations (61%), followed by the Mayo Clinic (38%), Harvard Medical School (36%), and Swedish (30%) study populations. For every study population, mutations in myosin binding protein C (MYBPC3) were the most common cause of HCM. Patients with a family history of MCM had mutations more frequently than those without. This pooled analysis revealed no statistically significant differences in left ventricular wall thickness or in mean age at diagnosis across all genotypes. CONCLUSIONS: Differentiation of sarcomeric genotypes, such as MYBPC3-HCM and MYH7-HCM, is not possible on the basis of currently reported phenotypic data. A myriad of genetic and/or environmental modifiers in addition to the primary disease-causing genetic substrate must play an important role in determining a patient's particular phenotype.
AB - OBJECTIVE: To pool results from studies of patients with hypertrophic cardiomyopathy (HCM) to elucidate important phenotypic differences among genotypes. MATERIAL AND METHODS: Data published from November 1998 through November 2004 were gathered and compared from unrelated study population genotyping studies from the Mayo Clinic (Rochester, Minn), Harvard Medical School (Boston, Mass), France, Germany, Sweden, Finland, and Spain. Standard statistical analysis techniques were used to pool and compare date across genotypes with respect to frequency of mutations, age at diagnosis, and degree of hypertrophy (left ventricular wall thickness). RESULTS: The French study populated harbored the highest frequency of mutations (61%), followed by the Mayo Clinic (38%), Harvard Medical School (36%), and Swedish (30%) study populations. For every study population, mutations in myosin binding protein C (MYBPC3) were the most common cause of HCM. Patients with a family history of MCM had mutations more frequently than those without. This pooled analysis revealed no statistically significant differences in left ventricular wall thickness or in mean age at diagnosis across all genotypes. CONCLUSIONS: Differentiation of sarcomeric genotypes, such as MYBPC3-HCM and MYH7-HCM, is not possible on the basis of currently reported phenotypic data. A myriad of genetic and/or environmental modifiers in addition to the primary disease-causing genetic substrate must play an important role in determining a patient's particular phenotype.
UR - http://www.scopus.com/inward/record.url?scp=16344385637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16344385637&partnerID=8YFLogxK
U2 - 10.4065/80.4.463
DO - 10.4065/80.4.463
M3 - Article
C2 - 15819282
AN - SCOPUS:16344385637
SN - 0025-6196
VL - 80
SP - 463
EP - 469
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 4
ER -